An interventional study of Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft and Endovascular repair of ascending/arch aortic aneurysm using branched stent graft in Aortic Aneurysm, Abdominal, Ascending Aorta Aneurysm and Aortic Arch Aneurysm, sponsored by University of North Carolina, Chapel Hill. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Aortic Aneurysm, Abdominal with a site in United States — 28 open to participants now, 34 under way, 1 of them phase 3. Aortic Aneurysm, Abdominal · United States.
Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, this one is the 3rd largest by planned enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2012, is one of 64 with no phase, reaches primary completion later than 30 of the 33 other live ones, and was the 48th registered.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
Browse Aortic Aneurysm, Abdominal studies →28 of the 122 studies in Aortic Aneurysm, Abdominal with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
Aiatella Oy · Sites in United States, Brazil
Ages 22+ · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18+ · Healthy volunteers
Steven Maximus · Sites in United States
Ages 18+
Cali Johnson · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 8 · Phase 3 2 · Phase 4 4
First in 1998; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 770 is above the median of 66 across 228 interventional studies indexed under Aortic Aneurysm, Abdominal.
Median enrollment 94 across the 85 interventional studies, 210 across the 32 observational. Of the 74 that completed or were terminated, 39 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 122 have an industry lead sponsor. The 10 most frequent:
University of North Carolina, Chapel Hill is the lead sponsor of 1,373 studies on the registry; 134 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 140 (86%) have results posted.
University of North Carolina, Chapel Hill has 1 study filed under Aortic Aneurysm, Abdominal — fewer than ten, so there is no comparison to draw.
9 of the studies in Aortic Aneurysm, Abdominal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04875429Cook Research IncorporatedZenith® Fenestrated+ Clinical Study | 2026-11 |
| NCT03446287Mayo ClinicClinical Outcomes of Patients Treated With Open Surgical Repair for Complex Aortic Aneurysms | 2026-12 |
| NCT05004051ViTAA Medical SolutionsViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA | 2026-12-31 |
| NCT07473102Washington University School of MedicinePET Imaging of MMP Activation in AAA: Clinical Component | 2027-03-31 |
| NCT06990048EndologixThe Long-Term EVAR Assessment and Follow-Up (LEAF) Study for the AFX2 System | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate visceral function, after endovascular repair of thoracoabdominal aneurysms or ascending/aortic arch aneurysms.
This study will evaluate the effect of endovascular repair of thoracoabdominal aortic aneurysms (Types I-IV) on visceral function or aortic arch aneurysms using custom manufactured and off the shelf stent grafts. Specifically, the device orientation and configuration will be evaluated with respect to renal function. Since detailed CT scan imaging will be performed prior to and after endovascular repair, critical data concerning each branched vessel length, tangential orientation from the aorta, angle of incidence, and diameter can be determined. This information can then be coupled with hemodynamic data obtained from duplex ultrasonography as well as changes in renal volume, estimated glomerular filtration rate (eGFR), and flow characteristics over time. By analyzing the data in this fashion, it may be possible to determine changes in hemodynamics and/or physiologic conditions with respect to branched stent-graft design characteristics. These data may be utilized to enhance current device design and improve patient outcomes. The FDA has approved the use of commercially available devices to be used in conjunction with the investigational device if the Investigator deems this necessary.
Cohort 1 (TAAA) Inclusion Criteria:
Patients may be included in the study if the patient has at least one of the following and has aortic anatomy appropriate for treatment with the Zenith® p-Branch™, Zenith® t-Branch, or Physician Specified TAAA Endovascular Graft (Custom Manufactured Devices).
Aortic Aneurysm Diameter
a. TAAA (Type I - IV) (including pararenal subtypes) with orthogonal aortic diameter greater than or equal to 5 cm or b. greater than two times the normal aortic diameter
Exclusion Criteria:
General Exclusion Criteria
Patients must be excluded from the study if any of the following conditions are true:
Medical Exclusion Criteria
Patients must be excluded from the study if any of the following conditions are true:
1) Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin, silver), polypropylene, urethane or gold 2) History of anaphylactic reaction to contrast material that cannot be adequately premedicated 3) Leaking, ruptured aneurysm associated with hypotension 4) Uncorrectable coagulopathy
Anatomical Exclusion Criteria
Patients must be excluded from the study if any of the following conditions are true:
Does not have a non-aneurysmal aortic segment proximal to the aneurysm with:
a. A length of at least 4 mm, i.e. at least 4 mm circumferential wall contact around the limits of scallop b. A diameter measured outer wall to outer wall of no greater than 31mm and no less than 21 mm; c. An angle less than 60 degrees relative to the centerline of the aneurysm; d. An angle less than 45 degrees relative to the supraceliac aorta.
Does not have visceral vessel anatomy compatible with Zenith® p-Branch™, specifically:
a. Renal vessel origins as measured relative to the superior mesenteric artery (SMA) compatible with the renal fenestration, i.e. Both renal vessel origins within 7.5mm of the corresponding renal fenestrations; b. Celiac vessel origin as measured relative to the superior mesenteric artery (SMA) compatible with the celiac scallop.
Does not have iliac artery fixation sites and anatomy consistent with:
Inability to preserve at least one hypogastric artery
-
Cohort 2 (ascending/aortic arch) Inclusion Criteria:
General Inclusion Criteria:
Patient determined to be a high-risk profile for open surgical repair considering any of the following items:
Vascular Inclusion Criteria:
Anatomic Inclusion Criteria:
1) There is enough space for the device to be deployed distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion 2) Ascending aortic length >50 mm (greater curve distance from sinotubular junction to proximal aspect of the innominate artery) 3) Sealing zone in the ascending aorta >40 mm in length and \<38 mm in diameter for native aorta (\<42 mm if surgical graft replacement in place) 4) Sealing zone in the great vessels of >20 mm in length
Diameter of CCA or subclavian artery used for sealing \< 16mm 5. Distal aortic fixation zone: Native aorta or surgical graft (endovascular device or Dacron graft) , diameter: 20-42mm, distal neck length ≥20mm 6) Access for device delivery to accommodate 22F or 24F sheath depending on device design.
7) Sealing zone in the great vessels of ≥ 20 mm in length
Extra inclusion criteria - special situations:
Aortic dissection:
If more distal disease is observed in the aorta
Exclusion Criteria:
General exclusion criteria:
Anatomic Exclusion Criteria for the Cook Ascending/Arch graft
Proximal seal site with a circumferential thrombus/atheroma/calcium
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using Branched stent grafts
Device: Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft
Endovascular repair of aortic ascending/arch aneurysm using branched stent grafts
Device: Endovascular repair of ascending/arch aortic aneurysm using branched stent graft
Repair of thoracoabdominal aortic aneurysms
Also known as: Endovascular repair of thoracoabdominal aortic aneurysm
Repair of ascending/arch aortic aneurysms
Also known as: Endovascular repair of ascending/ arch aortic aneurysm
Change from baseline in renal function over time (up to two years) after endovascular aortic aneurysm repair various custom stent grafts
Visceral function after endovascular repair of pararenal aneurysms using various custom stent grafts. Specifically, the device orientation and configuration will be evaluated with respect to renal function over time. Critical data concerning each branched vessel from radiological studies coupled with hemodynamic data obtained from renal artery duplex, changes in renal volume, eGFR, and flow characteristics at 1, 6, 12, 18 and 24 months post procedure may make it possible to determine changes in renal function.
Time frame: Pre-procedure and 1, 6, 12, 18, and 24 months post procedure
Time to morbidity
Morbidity at 30 days, 1 \& 2 years post procedure
Time frame: 30 days and 1 & 2 years post procedure
Time to mortality
Mortality at 30 days, 1 \& 2 years post procedure.
Time frame: 30 days and 1 & 2 years post procedure
Time to loss of stent graft integrity
Evidence on contrast CT angiography of loss of stent graft integrity at 30 days, and one and two years post procedure.
Time frame: 30 days and 1 & 2 years post procedure
Time to migration
Evidence of stent graft migration on abdominal x-rays at 30 days and 1 \& 2 years.
Time frame: 30 days and 1 & 2 years post procedure
Endoleak
Evidence of Endoleak on contrast CT angiography of abdomen 30 days and 1 \& 2 years post procedure.
Time frame: 30 days and 1 & 2 years post procedure
Branch vessel Events
Evidence of branch vessel events on contrast CT angiography and renal duplex 30 days, and 1 \& 2 years post procedure.
Time frame: 30 days and 1 & 2 years post procedure
The record gives a start of Jul 2012, a primary completion of Aug 2035 and a completion of Aug 2035. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →